SB 220025 三盐酸盐

SB 220025 trihydrochloride may be used in p38-mediated cell signaling studies.

SB 220025 is a potent, specific inhibitor of human p38 MAP kinase (IC₅₀ = 60 nM).

SB 220025 is a potent, specific inhibitor of human p38 mitogen-activated protein (MAP) kinase, with an IC₅₀ value of 60 nM and 50- to 1000-fold selectivity. SB 220025 reduces inflammatory cytokine production and inhibits angiogenesis. SB 220025 reduced the lipopolysaccharide-induced production of TNF at an ED₅₀ value of 7.5 mg/kg. At 30 mg/kg, SB 220025 reduced the expression of TNF and inhibited angiogenesis by ~40%. In a further study, the effects of p38/CSBP MAP kinase inhibition in angiogenesis-dependent chronic inflammatory disease was tested in murine collagen-induced arthritis and SB 220025 was able to prevent the progression of established arthritis.

This compound is featured on the MAPKs page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.